BR-4628 / Bayer - LARVOL DELTA

Therapeutic perspective-evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease. (PubMed, Am J Physiol Endocrinol Metab) - "Finerenone, a novel and selective non-steroidal mineralocorticoid receptor antagonist (NS-MRA), was approved for treatment of patients with DKD, and is associated with lower rates of hyperkalemia. Other NS-MRAs (such as KBP-5074, BR-4628, esaxerenone, and apararenone) may also be effective drugs for treatment of DKD. This review summarizes the effects of pharmacological MR blockade on diabetes and diabetes-associated CKD, with a particular focus on the therapeutic mechanisms of NS-MRAs in preclinical studies and ongoing clinical studies. Further investigation of combined treatment with renoprotective drugs and NS-MRAs to improve treatment of DKD is needed."

Journal • Review • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus